European respiratory review : an official journal of the European Respiratory Society · 2026
Respiratory support in paediatric patients with bronchiolitis: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karageorgos Spyridon, Chantzaras Anastasios Panagiotis, Agouridis Aris P, Beegan Aidan, O'Shea Nicola, Davis Tessa, Barrett Michael
Аннотация
BACKGROUND: Recent evidence suggests that high-flow nasal cannula (HFNC) may confer better clinical outcomes compared with other respiratory support modalities in paediatric patients with bronchiolitis.
METHODS: We performed a literature search up to 21 January 2024 on PubMed, Scopus, Cochrane Library, Embase, Cumulative Index to Nursing and Allied Health Literature, World Health Organization International Clinical Trials Registry Platform and Clinicaltrials.gov. Randomised controlled studies including paediatric patients aged ≤24 months with bronchiolitis comparing the use of HFNC versus low-flow nasal cannula (LFNC) or continuous positive airway pressure (CPAP) were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Random-effect modelling was used to estimate pooled effects.
RESULTS: 18 studies with 4094 patients were included. HFNC did not reduce the need for mechanical ventilation compared to LFNC (risk ratio 0.69, 95% CI 0.33-1.44; p=0.32) or CPAP (risk ratio 0.90, 95% CI 0.65-1.24; p=0.52). HFNC resulted in less treatment failure compared to LFNC (risk ratio 0.44, 95% CI 0.23-0.87; p=0.02), whereas there was no difference compared to CPAP (risk ratio 1.28, 95% CI 0.90-1.80; p=0.17). HFNC was associated with significant reduction in length of paediatric intensive care unit (PICU) stay compared to LFNC (mean difference (MD) -0.40 95% CI -0.78- -0.02; p=0.04), but not compared to CPAP (MD -0.24, 95% CI -0.91-0.43; p=0.47).
INTERPRETATION: HFNC significantly reduced treatment failure, length of PICU stay and total oxygen therapy duration compared to LFNC. No differences between HFNC and CPAP in primary and secondary outcomes. HFNC could be considered as initial treatment modality in paediatric patients with bronchiolitis, especially in patients requiring escalation of treatment from LFNC.
METHODS: We performed a literature search up to 21 January 2024 on PubMed, Scopus, Cochrane Library, Embase, Cumulative Index to Nursing and Allied Health Literature, World Health Organization International Clinical Trials Registry Platform and Clinicaltrials.gov. Randomised controlled studies including paediatric patients aged ≤24 months with bronchiolitis comparing the use of HFNC versus low-flow nasal cannula (LFNC) or continuous positive airway pressure (CPAP) were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Random-effect modelling was used to estimate pooled effects.
RESULTS: 18 studies with 4094 patients were included. HFNC did not reduce the need for mechanical ventilation compared to LFNC (risk ratio 0.69, 95% CI 0.33-1.44; p=0.32) or CPAP (risk ratio 0.90, 95% CI 0.65-1.24; p=0.52). HFNC resulted in less treatment failure compared to LFNC (risk ratio 0.44, 95% CI 0.23-0.87; p=0.02), whereas there was no difference compared to CPAP (risk ratio 1.28, 95% CI 0.90-1.80; p=0.17). HFNC was associated with significant reduction in length of paediatric intensive care unit (PICU) stay compared to LFNC (mean difference (MD) -0.40 95% CI -0.78- -0.02; p=0.04), but not compared to CPAP (MD -0.24, 95% CI -0.91-0.43; p=0.47).
INTERPRETATION: HFNC significantly reduced treatment failure, length of PICU stay and total oxygen therapy duration compared to LFNC. No differences between HFNC and CPAP in primary and secondary outcomes. HFNC could be considered as initial treatment modality in paediatric patients with bronchiolitis, especially in patients requiring escalation of treatment from LFNC.